Steatohepatitis/Metabolic Liver Disease News

A novel GaINAc-conjugated RNAi therapeutic meant to replicate the protective nature of a mutation showed promising efficacy in a proof-of-concept study in the first five patients treated with the medication.

Resmetirom rapidly reduced hepatic fat, fibrosis and biomarkers among patients with nonalcoholic steatohepatitis, according to a presentation at the International Liver Congress.

Researchers saw higher reduction in steatosis and body weight with the low-carb high-fat and 5:2 diets compared with the standard of care in patients with nonalcoholic fatty liver disease, according to a presentation at the International Liver Congress.

Patients with metabolic-associated fatty liver disease or higher transaminases who were then diagnosed with COVID-19 were more likely to die, according to a presenter at the International Liver Congress

Independent risk factors for COVID-19 mortality included chronic liver disease and alcohol use disorders, which also contributed to disease burden in 2020, according to a presenter at the International Liver Congress.

Only 56% of patients with nonalcoholic fatty liver disease were taking guidelines-recommended statin therapy, according to a study published in Clinical Gastroenterology and Hepatology.

An oral hydrogel capsule for treatment of obesity may reduce liver fibrosis risk, according to an exploratory analysis of the GLOW study presented at the American Association of Clinical Endocrinology annual meeting.

Two-year therapy with testosterone undecanoate normalized serum testosterone levels and reduced nonalcoholic fatty liver disease grade among men with obesity, functional hypogonadism and type 2 diabetes, data show.

In an exclusive video with Healio Gastroenterology, Eric Lawitz, MD, from the Texas Liver Institute, The University of Texas Health, San Antonio, spoke about the NAVIGATE trial in nonalcoholic steatohepatitis-related cirrhosis.

Prevalence of fatty liver in the United States increased significantly between 1999 and 2016 with high- and moderate-risk groups also growing, according to a presentation at Digestive Diseases Week.